We are also aware of the fact that our experimental models mimic AML in which the CEBPA p30 variant constitutes the sole CEBPA entity, which is different from the combination of N- and C-terminal mutations that constitutes the bulk of human CEBPADM AML cases. Here, CEBPA is linked to acute myeloid leukemia.